Compare REGN & NOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | NOC |
|---|---|---|
| Founded | 1988 | 1939 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 81.8B |
| IPO Year | 1995 | 2002 |
| Metric | REGN | NOC |
|---|---|---|
| Price | $796.95 | $578.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 16 |
| Target Price | ★ $830.16 | $697.38 |
| AVG Volume (30 Days) | 764.3K | ★ 849.8K |
| Earning Date | 04-29-2026 | 04-21-2026 |
| Dividend Yield | 0.55% | ★ 1.61% |
| EPS Growth | ★ 8.19 | 2.61 |
| EPS | ★ 18.95 | 13.83 |
| Revenue | $5,872,227,000.00 | ★ $41,954,000,000.00 |
| Revenue This Year | $12.45 | $5.68 |
| Revenue Next Year | $10.13 | $6.20 |
| P/E Ratio | $42.06 | ★ $41.63 |
| Revenue Growth | ★ 20.82 | 2.24 |
| 52 Week Low | $541.00 | $479.02 |
| 52 Week High | $821.11 | $774.00 |
| Indicator | REGN | NOC |
|---|---|---|
| Relative Strength Index (RSI) | 77.83 | 67.92 |
| Support Level | $738.17 | $545.34 |
| Resistance Level | $818.06 | $584.95 |
| Average True Range (ATR) | 21.79 | 12.31 |
| MACD | 7.78 | 4.39 |
| Stochastic Oscillator | 91.45 | 94.99 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Northrop Grumman is a diversified defense contractor providing aeronautics, defense, and space systems. The company's aerospace segment produces autonomous and piloted aircraft such as Global Hawk drones and the new B-21 bomber, creates the fuselage for the massive F-35 program, and maintains and upgrades numerous other military aircraft. Defense systems makes artillery and missile ammunition and guidance systems, long-range missiles, and missile defense systems. Mission systems creates and integrates a variety of radar, navigation, and communication systems for avionics, weapons control, and countermeasures on a range of platforms from helicopters to destroyers. Space systems produces satellites, sensors, space structures, and rocket motors.